Carcinoma

Oncology
11
Pipeline Programs
10
Companies
10
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
2
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 8 programs with unclassified modality

On Market (2)

Approved therapies currently available

Bayer
NEXAVARApproved
sorafenib
Bayer
Kinase Inhibitor [EPC]oral2005
U
SORAFENIB TOSYLATEApproved
sorafenib
Unknown Company
Kinase Inhibitor [EPC]oral2022

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
SorafenibPhase 3Small Molecule1 trial
Active Trials
NCT00863746Completed703Est. Apr 2013
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
SavolitinibPhase 3Small Molecule1 trial
Active Trials
NCT03091192Active Not Recruiting60Est. Dec 2026
CT
1 program
1
Anlotinib hydrochloride capsulePhase 21 trial
Active Trials
NCT05494060RecruitingEst. Feb 2027
UP
UCB PharmaBelgium - Brussels
1 program
1
CarboplatinPhase 21 trial
Active Trials
NCT00152477Completed165Est. Jun 2009
Evopoint Biosciences
Evopoint BiosciencesChina - Beijing
1 program
1
XNW5004Phase 1/21 trial
Active Trials
NCT06022757Recruiting204Est. Aug 2028
Astellas
AstellasChina - Shenyang
2 programs
2
AGS-8M4Phase 11 trial
AGS-8M4Phase 11 trial
Active Trials
NCT01016054Terminated4Est. Apr 2010
NCT00816764Completed18Est. Jun 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
ARQ 501Phase 11 trial
Active Trials
NCT00099190Completed50Est. Nov 2006
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Sorafenib 100 mgPhase 11 trial
Active Trials
NCT00941863Completed158Est. Apr 2008
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer PatientsN/A1 trial
Active Trials
NCT03664843UnknownEst. Sep 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaSavolitinib
BayerSorafenib
Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule
UCB PharmaCarboplatin
Evopoint BiosciencesXNW5004
AstellasAGS-8M4
AstellasAGS-8M4
Merck & Co.ARQ 501
AmgenSorafenib 100 mg
City TherapeuticsCirculating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

Clinical Trials (10)

Total enrollment: 1,362 patients across 10 trials

NCT03091192AstraZenecaSavolitinib

Savolitinib vs. Sunitinib in MET-driven PRCC.

Start: Jul 2017Est. completion: Dec 202660 patients
Phase 3Active Not Recruiting
NCT00863746BayerSorafenib

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Start: Apr 2009Est. completion: Apr 2013703 patients
Phase 3Completed
NCT05494060Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Start: Mar 2022Est. completion: Feb 2027
Phase 2Recruiting
NCT00152477UCB PharmaCarboplatin

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Start: Aug 2005Est. completion: Jun 2009165 patients
Phase 2Completed
NCT06022757Evopoint BiosciencesXNW5004

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Start: Sep 2023Est. completion: Aug 2028204 patients
Phase 1/2Recruiting
NCT01016054AstellasAGS-8M4

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Start: Oct 2009Est. completion: Apr 20104 patients
Phase 1Terminated
NCT00816764AstellasAGS-8M4

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer

Start: Oct 2008Est. completion: Jun 201018 patients
Phase 1Completed
NCT00099190Merck & Co.ARQ 501

ARQ 501 in Combination With Docetaxel in Patients With Cancer

Start: Dec 2004Est. completion: Nov 200650 patients
Phase 1Completed
NCT00941863AmgenSorafenib 100 mg

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Start: Jul 2002Est. completion: Apr 2008158 patients
Phase 1Completed
NCT03664843City TherapeuticsCirculating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

Start: Nov 2018Est. completion: Sep 2020
N/AUnknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
12m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,362 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)